Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products
The use of live biotherapeutic products (LBPs), including single strains of beneficial probiotic bacteria or consortiums, is gaining traction as a viable option to treat inflammatory-mediated diseases like inflammatory bowel disease (IBD). However, LBPs’ persistence in the intestine is heterogeneous...
Main Authors: | Jiayu Ye, Lauren A. E. Erland, Sandeep K. Gill, Stephanie L. Bishop, Andrea Verdugo-Meza, Susan J. Murch, Deanna L. Gibson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/11/5/738 |
Similar Items
-
Clinical application of live biotherapeutic products in infectious diseases
by: Bhagyashri D. Navalkele, et al.
Published: (2024-07-01) -
Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions
by: Duygu Ağagündüz, et al.
Published: (2022-10-01) -
Lachnospiraceae are emerging industrial biocatalysts and biotherapeutics
by: Tom Zaplana, et al.
Published: (2024-01-01) -
Nanobodies as potential tools for microbiological testing of live biotherapeutic products
by: Robert J. Dorosky, et al.
Published: (2024-01-01) -
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
by: Kyle P. Martin, et al.
Published: (2023-12-01)